carglumic acid — CareFirst (Caremark)

Initial criteria

• The diagnosis is confirmed by enzymatic, biochemical, or genetic testing
• The member has elevated plasma ammonia levels at baseline

Reauthorization criteria

• Member is experiencing benefit from therapy as evidenced by a decrease in ammonia levels from baseline

Approval duration

12 months